文献速递核素与放射性配体治疗肿瘤 PET/CT

177Lu-DOTATATE治疗后DNA损伤修复的在体显像

Imaging DNA Damage Repair In Vivo After 177Lu-DOTATATE Therapy.
PubMed 文献 · J Nucl Med · 2019-11-22

本研究以111In-anti-γH2AX-TAT SPECT显像在体外细胞和小鼠肿瘤模型中可视化和量化177Lu-DOTATATE治疗后的DNA损伤应答,属于该在体生物剂量计的首次原理验证。结果显示克隆存活与外照射后的内在放射敏感性呈细胞系特异性,177Lu-DOTATATE处理后SSTR2高表达细胞的克隆存活下降、γH2AX焦点增加。离体测量显示CA20948异种移植瘤不同区域中177Lu-DOTATATE摄取与γH2AX焦点诱导仅部分相关,提示肿瘤不同部位对照射的反应存在差异。

要点

  • 111In-anti-γH2AX-TAT可用于监测177Lu-DOTATATE治疗后的DNA损伤。
  • SSTR2高表达细胞经177Lu-DOTATATE处理后克隆存活下降、γH2AX焦点增加。
  • CA20948肿瘤不同区域的摄取与γH2AX焦点诱导仅部分相关,提示损伤反应异质。

核心结论

  • 111In-anti-γH2AX-TAT可监测177Lu-DOTATATE治疗后的DNA损伤并揭示异质性损伤反应。

研究设计与样本

  • 原理验证研究:6种细胞系接受外照射或177Lu-DOTATATE处理,测量γH2AX焦点数与克隆存活。
  • 荷CA20948生长抑素受体阳性异种移植瘤小鼠接受177Lu-DOTATATE或假处理,并共注射111In-anti-γH2AX-TAT、111In-IgG-TAT对照或溶媒。

主要发现

  • 外照射后克隆存活呈细胞系特异性,提示内在放射敏感性水平不同。
  • 177Lu-DOTATATE处理后,SSTR2高表达细胞的克隆存活下降、γH2AX焦点增加。
  • 离体测量显示CA20948异种移植瘤不同区域中177Lu-DOTATATE摄取与γH2AX焦点诱导仅部分相关。

关键数值与推荐

  • 外照射后克隆存活为细胞系特异性,提示不同细胞系内在放射敏感性存在差异。
  • 177Lu-DOTATATE处理后SSTR2高表达细胞克隆存活下降且γH2AX焦点增加。
  • CA20948肿瘤不同区域中177Lu-DOTATATE摄取与γH2AX焦点诱导仅部分相关。

临床怎么用

  • 该在体生物剂量计可为177Lu-DOTATATE治疗计划与给药提供放射生物学参考的探索性工具。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Molecular radiotherapy using 177Lu-DOTATATE is a most effective treatment for somatostatin receptor-expressing neuroendocrine tumors. Despite its frequent and successful use in the clinic, little or no radiobiologic considerations are made at the time of treatment planning or delivery. On positive uptake on octreotide-based PET/SPECT imaging, treatment is usually administered as a standard dose and number of cycles without adjustment for peptide uptake, dosimetry, or radiobiologic and DNA damage effects in the tumor. Here, we visualized and quantified the extent of DNA damage response after 177Lu-DOTATATE therapy using SPECT imaging with 111In-anti-γH2AX-TAT. This work was a proof-of-principle study of this in vivo noninvasive biodosimeter with β-emitting therapeutic radiopharmaceuticals. Methods: Six cell lines were exposed to external-beam radiotherapy (EBRT) or 177Lu-DOTATATE, after which the number of γH2AX foci and the clonogenic survival were measured. Mice bearing CA20948 somatostatin receptor-positive tumor xenografts were treated with 177Lu-DOTATATE or sham-treated and coinjected with 111In-anti-γH2AX-TAT, 111In-IgG-TAT control, or vehicle. Results: Clonogenic survival after external-beam radiotherapy was cell-line-specific, indicating varying levels of intrinsic radiosensitivity. Regarding in vitro cell lines treated with 177Lu-DOTATATE, clonogenic survival decreased and γH2AX foci increased for cells expressing high levels of somatostatin receptor subtype 2. Ex vivo measurements revealed a partial correlation between 177Lu-DOTATATE uptake and γH2AX focus induction between different regions of CA20948 xenograft tumors, suggesting that different parts of the tumor may react differentially to 177Lu-DOTATATE irradiation. Conclusion:111In-anti-γH2AX-TAT allows monitoring of DNA damage after 177Lu-DOTATATE therapy and reveals heterogeneous damage responses.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. O'Neill E, Kersemans V, Allen PD, et al. Imaging DNA Damage Repair In Vivo After 177Lu-DOTATATE Therapy. J Nucl Med. 2019. PMID: 31757844. doi:10.2967/jnumed.119.232934

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。